Takeover target Shire promises strong growth

June 23, 2014

Takeover target Shire on Monday highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie.

Chief Executive Flemming Ornskov told analysts that Shire PLC should remain independent, and that it expects to more than double its 2013 annual product sales to $10 billion by 2020.

The company, which is known for its rare disease drugs, has rejected an unsolicited 27 billion-pound ($46.2 billion) offer from AbbVie Inc., arguing it fundamentally undervalues the company. It also expressed concern that AbbVie was interested in the move for tax reasons.

Shire has so far rejected three overtures.

The offer comes at a time of wheeling and dealing in the pharmaceutical industry, as drugmakers look to grow or eliminate noncore assets while focusing on strengths.

Alex Arfaei, a pharmaceutical analyst for BMO Nesbitt Burns Inc., said acquiring Shire would "meaningfully improve" AbbVie's business.

"Overall, we were encouraged by the tone of the Shire call, and believe that a friendly offer could be possible," Arfaei wrote. "We believe that AbbVie does have room to meaningfully sweeten its offer."

He estimated that AbbVie could increase the cash component of its offer from 20.44 pounds per share to 34 pounds, which would value Shire at just under 60 pounds per share, or $60 billion.

Explore further: Shire buys ViroPharma in $4.2 billion deal (Update)

Related Stories

Shire buys ViroPharma in $4.2 billion deal (Update)

November 11, 2013
The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.

AstraZeneca rejects $119 billion offer from Pfizer (Update)

May 19, 2014
The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively ...

Pfizer pulls plug on push to buy AstraZeneca (Update 2)

May 26, 2014
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.

AstraZeneca rejects sweetened Pfizer takeover bid (Update)

May 2, 2014
Pharmaceutical giant Pfizer said Friday that it hasn't given up on a deal after British drugmaker AstraZeneca flatly rejected its latest takeover bid, worth $106 billion.

Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014
Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about a deal.

Allergan board rebuffs latest Valeant offer (Update)

June 10, 2014
Allergan's board has unanimously rejected the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker said the offer isn't even worth talking about.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.